Neumora Therapeutics Discounted Cash Flow

Neumora Therapeutics (NMRA) currently reports a DCF fair value of $1.1. Use the charts on this page to explore Neumora Therapeutics's DCF fair value history and peer comparisons.

Neumora Therapeutics's discounted cash flow (DCF) fair value estimate is $1.1, about 19.3% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $1.1, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neumora Therapeutics, and consider following NMRA for alerts when major investors trade the stock.